| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Behavior, Animal | 9 | 2024 | 476 | 1.670 |
Why?
|
| Seizures | 7 | 2023 | 874 | 1.580 |
Why?
|
| Stress, Psychological | 14 | 2014 | 556 | 1.310 |
Why?
|
| Ventral Tegmental Area | 8 | 2017 | 50 | 1.220 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2024 | 352 | 1.220 |
Why?
|
| Epilepsy | 4 | 2025 | 858 | 1.200 |
Why?
|
| Depression | 9 | 2020 | 1227 | 1.060 |
Why?
|
| Lafora Disease | 1 | 2024 | 3 | 0.940 |
Why?
|
| Social Behavior | 5 | 2017 | 207 | 0.900 |
Why?
|
| Nucleus Accumbens | 13 | 2012 | 54 | 0.860 |
Why?
|
| Neurobiology | 3 | 2014 | 25 | 0.860 |
Why?
|
| Motor Disorders | 1 | 2022 | 5 | 0.820 |
Why?
|
| Epilepsies, Partial | 1 | 2023 | 91 | 0.810 |
Why?
|
| Epilepsy, Absence | 1 | 2022 | 31 | 0.790 |
Why?
|
| Brain | 8 | 2024 | 2967 | 0.770 |
Why?
|
| Cerebellar Ataxia | 1 | 2022 | 65 | 0.770 |
Why?
|
| Brain Ischemia | 2 | 2014 | 258 | 0.740 |
Why?
|
| Disabled Persons | 1 | 2022 | 99 | 0.740 |
Why?
|
| Brain-Derived Neurotrophic Factor | 7 | 2014 | 117 | 0.690 |
Why?
|
| Mice, Knockout | 6 | 2024 | 3722 | 0.620 |
Why?
|
| Anticonvulsants | 4 | 2024 | 376 | 0.580 |
Why?
|
| Down-Regulation | 4 | 2017 | 697 | 0.560 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 361 | 0.560 |
Why?
|
| Disease Models, Animal | 12 | 2025 | 4288 | 0.560 |
Why?
|
| Protein Precursors | 2 | 2017 | 149 | 0.550 |
Why?
|
| Stroke | 2 | 2014 | 956 | 0.520 |
Why?
|
| Depressive Disorder, Major | 2 | 2011 | 399 | 0.500 |
Why?
|
| Mice | 28 | 2025 | 17542 | 0.470 |
Why?
|
| Reward | 5 | 2010 | 107 | 0.460 |
Why?
|
| Brain Diseases, Metabolic | 1 | 2013 | 12 | 0.450 |
Why?
|
| Animals | 34 | 2025 | 33798 | 0.450 |
Why?
|
| Autistic Disorder | 1 | 2017 | 346 | 0.440 |
Why?
|
| Disease Susceptibility | 2 | 2014 | 297 | 0.430 |
Why?
|
| Delirium | 1 | 2013 | 47 | 0.430 |
Why?
|
| Bradycardia | 1 | 2013 | 59 | 0.420 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2012 | 9 | 0.420 |
Why?
|
| Anxiety | 4 | 2020 | 961 | 0.410 |
Why?
|
| Fear | 1 | 2014 | 201 | 0.410 |
Why?
|
| Avoidance Learning | 3 | 2012 | 56 | 0.400 |
Why?
|
| Nerve Tissue Proteins | 2 | 2025 | 1112 | 0.400 |
Why?
|
| Affect | 2 | 2023 | 157 | 0.380 |
Why?
|
| Adaptation, Physiological | 4 | 2011 | 260 | 0.380 |
Why?
|
| Adenylyl Cyclases | 2 | 2008 | 75 | 0.380 |
Why?
|
| Antidepressive Agents | 6 | 2011 | 288 | 0.370 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2013 | 248 | 0.370 |
Why?
|
| Mice, Inbred C57BL | 15 | 2024 | 4357 | 0.340 |
Why?
|
| Electrocardiography | 1 | 2013 | 957 | 0.300 |
Why?
|
| Electroencephalography | 5 | 2023 | 857 | 0.260 |
Why?
|
| Brain Mapping | 2 | 2023 | 397 | 0.260 |
Why?
|
| Glutamic Acid | 3 | 2017 | 200 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 488 | 0.250 |
Why?
|
| Male | 24 | 2025 | 60173 | 0.250 |
Why?
|
| Anxiety Disorders | 3 | 2020 | 677 | 0.240 |
Why?
|
| Psychiatry | 1 | 2008 | 263 | 0.240 |
Why?
|
| Depressive Disorder | 1 | 2008 | 451 | 0.240 |
Why?
|
| Neurons | 8 | 2017 | 1938 | 0.240 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2025 | 40 | 0.240 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2024 | 17 | 0.230 |
Why?
|
| Research Design | 1 | 2008 | 676 | 0.230 |
Why?
|
| Analysis of Variance | 8 | 2011 | 1009 | 0.230 |
Why?
|
| Inclusion Bodies | 1 | 2024 | 48 | 0.230 |
Why?
|
| Humans | 22 | 2025 | 123180 | 0.220 |
Why?
|
| Calcium | 1 | 2008 | 1096 | 0.210 |
Why?
|
| Actigraphy | 1 | 2023 | 44 | 0.210 |
Why?
|
| Dopamine | 4 | 2008 | 284 | 0.210 |
Why?
|
| Neurophysiology | 1 | 2022 | 20 | 0.200 |
Why?
|
| Scalp | 1 | 2022 | 56 | 0.190 |
Why?
|
| Neurotransmitter Agents | 2 | 2014 | 145 | 0.190 |
Why?
|
| Gene Expression Regulation, Enzymologic | 4 | 2011 | 256 | 0.180 |
Why?
|
| Ataxia | 1 | 2022 | 168 | 0.180 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2021 | 52 | 0.180 |
Why?
|
| Signal Transduction | 9 | 2011 | 4494 | 0.170 |
Why?
|
| Female | 14 | 2025 | 65562 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2023 | 3547 | 0.170 |
Why?
|
| Interpersonal Relations | 4 | 2011 | 227 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-fos | 3 | 2010 | 64 | 0.170 |
Why?
|
| Pentylenetetrazole | 1 | 2019 | 29 | 0.170 |
Why?
|
| NAV1.1 Voltage-Gated Sodium Channel | 1 | 2019 | 14 | 0.170 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2019 | 24 | 0.170 |
Why?
|
| Dominance-Subordination | 5 | 2010 | 10 | 0.160 |
Why?
|
| Cocaine | 3 | 2009 | 206 | 0.160 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2021 | 202 | 0.150 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2014 | 1214 | 0.150 |
Why?
|
| Escape Reaction | 2 | 2008 | 15 | 0.150 |
Why?
|
| NF-kappa B | 2 | 2009 | 457 | 0.130 |
Why?
|
| Dopamine Antagonists | 2 | 2014 | 50 | 0.130 |
Why?
|
| Dopamine Agonists | 2 | 2014 | 79 | 0.130 |
Why?
|
| Rats | 7 | 2014 | 3651 | 0.130 |
Why?
|
| Deep Brain Stimulation | 1 | 2021 | 399 | 0.130 |
Why?
|
| Trans-Activators | 2 | 2011 | 809 | 0.120 |
Why?
|
| Comorbidity | 1 | 2020 | 1497 | 0.120 |
Why?
|
| Plasminogen Activators | 1 | 2014 | 20 | 0.120 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2014 | 20 | 0.120 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2014 | 3 | 0.120 |
Why?
|
| Synaptic Transmission | 1 | 2017 | 348 | 0.120 |
Why?
|
| Cell Nucleus | 1 | 2017 | 674 | 0.120 |
Why?
|
| Sex Factors | 3 | 2013 | 1261 | 0.120 |
Why?
|
| RNA, Messenger | 3 | 2017 | 2809 | 0.110 |
Why?
|
| Epigenesis, Genetic | 2 | 2008 | 664 | 0.110 |
Why?
|
| Quality of Life | 1 | 2023 | 1924 | 0.110 |
Why?
|
| Period Circadian Proteins | 1 | 2012 | 28 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2014 | 393 | 0.100 |
Why?
|
| Bromodeoxyuridine | 2 | 2010 | 60 | 0.100 |
Why?
|
| Neurology | 1 | 2013 | 107 | 0.100 |
Why?
|
| Sucrose | 2 | 2009 | 39 | 0.100 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2008 | 34 | 0.100 |
Why?
|
| Swimming | 2 | 2008 | 21 | 0.090 |
Why?
|
| Morphine | 1 | 2011 | 88 | 0.090 |
Why?
|
| Social Isolation | 2 | 2009 | 41 | 0.090 |
Why?
|
| Dopaminergic Neurons | 1 | 2011 | 49 | 0.090 |
Why?
|
| Radiography | 1 | 2013 | 822 | 0.090 |
Why?
|
| Hypothalamus | 2 | 2010 | 216 | 0.090 |
Why?
|
| Neuropsychiatry | 1 | 2011 | 12 | 0.090 |
Why?
|
| Food Preferences | 2 | 2009 | 117 | 0.090 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 61 | 0.090 |
Why?
|
| Histone Deacetylases | 2 | 2009 | 114 | 0.090 |
Why?
|
| Corpus Striatum | 1 | 2010 | 89 | 0.090 |
Why?
|
| Receptors, Adrenergic, beta-3 | 1 | 2010 | 11 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 577 | 0.090 |
Why?
|
| Melanocortins | 1 | 2010 | 12 | 0.090 |
Why?
|
| Amygdala | 1 | 2010 | 81 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 134 | 0.080 |
Why?
|
| Neural Inhibition | 1 | 2010 | 105 | 0.080 |
Why?
|
| Fluoxetine | 4 | 2012 | 43 | 0.080 |
Why?
|
| Adult | 3 | 2023 | 29032 | 0.080 |
Why?
|
| Cerebrovascular Circulation | 1 | 2012 | 434 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2009 | 74 | 0.080 |
Why?
|
| Benzamides | 1 | 2009 | 106 | 0.080 |
Why?
|
| Resilience, Psychological | 1 | 2010 | 73 | 0.080 |
Why?
|
| Biogenic Monoamines | 1 | 2008 | 3 | 0.080 |
Why?
|
| Receptor, trkB | 1 | 2008 | 20 | 0.080 |
Why?
|
| Prefrontal Cortex | 1 | 2010 | 177 | 0.080 |
Why?
|
| CREB-Binding Protein | 1 | 2009 | 63 | 0.080 |
Why?
|
| Immobility Response, Tonic | 1 | 2008 | 2 | 0.080 |
Why?
|
| Neurosecretory Systems | 1 | 2008 | 23 | 0.080 |
Why?
|
| Neuroimmunomodulation | 1 | 2008 | 15 | 0.080 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2009 | 84 | 0.080 |
Why?
|
| Phenotype | 2 | 2008 | 4226 | 0.080 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2008 | 16 | 0.080 |
Why?
|
| Nerve Growth Factors | 1 | 2008 | 72 | 0.080 |
Why?
|
| Leptin | 1 | 2010 | 214 | 0.080 |
Why?
|
| Neuronal Plasticity | 1 | 2011 | 273 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1876 | 0.070 |
Why?
|
| Motor Activity | 2 | 2008 | 521 | 0.070 |
Why?
|
| Adaptation, Psychological | 2 | 2008 | 461 | 0.070 |
Why?
|
| Pyridines | 1 | 2009 | 224 | 0.070 |
Why?
|
| Neurogenesis | 1 | 2010 | 196 | 0.070 |
Why?
|
| Nerve Net | 1 | 2010 | 238 | 0.070 |
Why?
|
| Isoenzymes | 1 | 2008 | 223 | 0.070 |
Why?
|
| Glucocorticoids | 1 | 2010 | 377 | 0.070 |
Why?
|
| Periaqueductal Gray | 1 | 2007 | 5 | 0.070 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2008 | 85 | 0.070 |
Why?
|
| Helplessness, Learned | 1 | 2007 | 8 | 0.070 |
Why?
|
| Caloric Restriction | 1 | 2008 | 85 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 424 | 0.070 |
Why?
|
| Neuropeptides | 1 | 2008 | 114 | 0.070 |
Why?
|
| Neural Pathways | 1 | 2008 | 265 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2009 | 258 | 0.070 |
Why?
|
| In Vitro Techniques | 1 | 2008 | 966 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 570 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 2840 | 0.070 |
Why?
|
| Aged | 2 | 2014 | 19108 | 0.060 |
Why?
|
| Limbic System | 1 | 2006 | 22 | 0.060 |
Why?
|
| Cocaine-Related Disorders | 1 | 2007 | 202 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 555 | 0.060 |
Why?
|
| Phenylenediamines | 1 | 2025 | 25 | 0.060 |
Why?
|
| Circadian Rhythm | 1 | 2007 | 268 | 0.060 |
Why?
|
| Emotions | 2 | 2023 | 361 | 0.060 |
Why?
|
| Carbamates | 1 | 2025 | 58 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2009 | 816 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 807 | 0.060 |
Why?
|
| Endovascular Procedures | 1 | 2012 | 731 | 0.060 |
Why?
|
| Hippocampus | 1 | 2010 | 819 | 0.060 |
Why?
|
| Fructose | 1 | 2024 | 62 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2004 | 206 | 0.050 |
Why?
|
| Pyramidal Cells | 1 | 2025 | 167 | 0.050 |
Why?
|
| Mice, Transgenic | 4 | 2010 | 2394 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2011 | 826 | 0.050 |
Why?
|
| Bipolar Disorder | 1 | 2007 | 347 | 0.050 |
Why?
|
| Middle Aged | 2 | 2013 | 26015 | 0.050 |
Why?
|
| Cryoelectron Microscopy | 1 | 2025 | 212 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 6375 | 0.050 |
Why?
|
| Young Adult | 2 | 2013 | 8864 | 0.050 |
Why?
|
| Estradiol | 1 | 2004 | 536 | 0.050 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2024 | 226 | 0.050 |
Why?
|
| Brain Diseases | 1 | 2025 | 299 | 0.050 |
Why?
|
| Gene Expression Regulation | 5 | 2009 | 2524 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2008 | 2307 | 0.050 |
Why?
|
| Artifacts | 1 | 2021 | 104 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2004 | 880 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2009 | 1681 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2012 | 12142 | 0.040 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2024 | 492 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2012 | 664 | 0.040 |
Why?
|
| Obesity | 1 | 2010 | 2230 | 0.040 |
Why?
|
| Imipramine | 2 | 2009 | 18 | 0.040 |
Why?
|
| Gene Transfer Techniques | 2 | 2011 | 357 | 0.040 |
Why?
|
| Gene Expression Profiling | 3 | 2009 | 1679 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2009 | 861 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2013 | 16062 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2010 | 1100 | 0.030 |
Why?
|
| Histones | 2 | 2009 | 527 | 0.030 |
Why?
|
| Transplantation Chimera | 1 | 2014 | 39 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2010 | 1165 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 1012 | 0.030 |
Why?
|
| Allografts | 1 | 2014 | 192 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2014 | 170 | 0.030 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2012 | 36 | 0.030 |
Why?
|
| Mutation | 3 | 2012 | 5767 | 0.030 |
Why?
|
| Maze Learning | 1 | 2012 | 127 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2012 | 382 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 578 | 0.020 |
Why?
|
| Time Factors | 2 | 2014 | 6221 | 0.020 |
Why?
|
| Pregnancy | 1 | 2024 | 7146 | 0.020 |
Why?
|
| Endophenotypes | 1 | 2011 | 13 | 0.020 |
Why?
|
| Isoquinolines | 1 | 2011 | 40 | 0.020 |
Why?
|
| Exploratory Behavior | 1 | 2011 | 52 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 119 | 0.020 |
Why?
|
| Dendritic Spines | 1 | 2011 | 56 | 0.020 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2011 | 130 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2011 | 277 | 0.020 |
Why?
|
| Receptors, AMPA | 1 | 2010 | 49 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2011 | 250 | 0.020 |
Why?
|
| S Phase | 1 | 2010 | 73 | 0.020 |
Why?
|
| Species Specificity | 1 | 2011 | 548 | 0.020 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2010 | 28 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2009 | 11 | 0.020 |
Why?
|
| Histone Deacetylase 2 | 1 | 2009 | 16 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2009 | 56 | 0.020 |
Why?
|
| Sweetening Agents | 1 | 2009 | 33 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2011 | 348 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 394 | 0.020 |
Why?
|
| PC12 Cells | 1 | 2009 | 27 | 0.020 |
Why?
|
| Cell Death | 1 | 2010 | 242 | 0.020 |
Why?
|
| Conditioning, Operant | 1 | 2008 | 17 | 0.020 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2009 | 27 | 0.020 |
Why?
|
| Lac Operon | 1 | 2009 | 94 | 0.020 |
Why?
|
| Self Administration | 1 | 2008 | 43 | 0.020 |
Why?
|
| Phenanthridines | 1 | 2008 | 3 | 0.020 |
Why?
|
| Sincalide | 1 | 2008 | 4 | 0.020 |
Why?
|
| Cholecystokinin | 1 | 2008 | 14 | 0.020 |
Why?
|
| Sexual Behavior, Animal | 1 | 2009 | 87 | 0.020 |
Why?
|
| Enkephalins | 1 | 2008 | 20 | 0.020 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2008 | 22 | 0.020 |
Why?
|
| Affective Symptoms | 1 | 2009 | 60 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2009 | 182 | 0.020 |
Why?
|
| Orexins | 1 | 2008 | 7 | 0.020 |
Why?
|
| Benzazepines | 1 | 2008 | 64 | 0.020 |
Why?
|
| Potassium Channels | 1 | 2009 | 158 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 810 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 2008 | 104 | 0.020 |
Why?
|
| Integrases | 1 | 2008 | 161 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2008 | 239 | 0.020 |
Why?
|
| Substance P | 1 | 2007 | 34 | 0.020 |
Why?
|
| Acetylation | 1 | 2007 | 166 | 0.020 |
Why?
|
| Lithium Compounds | 1 | 2007 | 14 | 0.020 |
Why?
|
| CLOCK Proteins | 1 | 2007 | 28 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2007 | 58 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 1702 | 0.020 |
Why?
|
| Lithium | 1 | 2007 | 66 | 0.020 |
Why?
|
| Body Composition | 1 | 2010 | 513 | 0.020 |
Why?
|
| Behavioral Symptoms | 1 | 2007 | 25 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2007 | 64 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1290 | 0.020 |
Why?
|
| Locomotion | 1 | 2007 | 69 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2010 | 464 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2007 | 318 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2007 | 347 | 0.020 |
Why?
|
| RNA | 1 | 2009 | 569 | 0.020 |
Why?
|
| Densitometry | 1 | 2004 | 24 | 0.010 |
Why?
|
| Cricetulus | 1 | 2004 | 97 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2004 | 180 | 0.010 |
Why?
|
| CHO Cells | 1 | 2004 | 157 | 0.010 |
Why?
|
| COS Cells | 1 | 2004 | 273 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 1442 | 0.010 |
Why?
|
| Chromatin | 1 | 2007 | 554 | 0.010 |
Why?
|
| Cricetinae | 1 | 2004 | 410 | 0.010 |
Why?
|
| Aggression | 1 | 2006 | 225 | 0.010 |
Why?
|
| Aging | 1 | 2011 | 1176 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2004 | 617 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1688 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2009 | 3040 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2007 | 678 | 0.010 |
Why?
|
| Binding Sites | 1 | 2004 | 1292 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2011 | 2587 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2004 | 791 | 0.010 |
Why?
|
| Cell Line | 1 | 2004 | 2771 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 19111 | 0.010 |
Why?
|